Abstract 1584P
Background
The AIO-FLOT3 Trial suggested that conversion therapy might improve outcome in pts with metastatic gastric cancer (GC). We conducted this prospective, single-arm, phase II trial to improve conversion efficacy of ICIs combined with mFLOT regimen (fluorouracil, oxaliplatin, and nab-PTX) in pts with initially unresectable locally advanced or limited metastatic GC or GEJ adenocarcinoma.
Methods
Eligible pts received Cam 200mg, oxaliplatin 85 mg/m2, nab-PTX 125 mg/m2 or with trastuzumab if Her2 positive, each was an IV followed by fluorouracil 2400 mg/m2 as a 48-h continuous iv on day 1, every 2 weeks. Pts were assessed for tumor response and surgical feasibility every 3 cycles. The primary endpoint was R0 conversion rate.
Results
35 pts were enrolled up to 04/2023. 30 pts were evaluable. The median age was 50y. Male was 76.7%. The metastatic sites included liver 50.0% (15), retroperitoneal lymph nodes (LNs) 33.0% (10), axillary and supraclavicular LNs 6.7% (2), Krukenberg 3.3% (1), adrenal gland 3.3% (1), and locally advanced unresectable 10% (3). 7(23.3%) pts had two or more unresectable lesions. 4 pts were dMMR/MSI-H and 4 were Her2 positive. ORR was 86.7% and DCR was 96.7%. 25(83.3%) pts were assessed as resectable after conversion therapy. One pt refused surgery and 2 were cCR under observation. 22 pts (73.3%) received operation with R0 resection and no perioperative mortality. With 2 cCR included, R0 conversion rate was 80.0% (24/30). 5 pts (22.7%) achieved pCR and 12(54.5%) achieved MPR. Grade 3 AEs included 2 cases of rash, 1 case of adrenal insufficiency, 1 case each of ALT, AST elevation and febrile neutropenia. 1 pt was Grade 4 Neutrophil count decreased. (Table)
Table: 1584P
Response and surgical conversion, n (%) | N=30 | |
ORR | 26 (86.7) | |
CR | 2 (6.7) | |
PR | 24 (80.0) | |
DCR | 29 (96.7) | |
SD | 3 (10.0) | |
PD | 1 (3.3) | |
R0 conversion rate | 24 (80.0) | |
Pathological response | pCR | 5/22 (22.7) |
MPR | 12/22 (54.5) | |
cCR+pCR | 7 (23.3) |
Conclusions
Cam combined with mFLOT regimen safely induced a high conversion rate, with very high R0 resection, pCR and MPR. The findings warrant further prospective investigations.
Clinical trial identification
NCT04510064.
Editorial acknowledgement
Legal entity responsible for the study
Fudan University Shanghai Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1590P - Real-world gastric cancer (GC) in Latin America (LATAM) and Europe (EU)
Presenter: Berenice Freile
Session: Poster session 22
1591P - Gastric cancer in young patients under 40 years: 5-year analyses of Georgian cancer registry
Presenter: Tamar Esakia
Session: Poster session 22
1617P - PRODIGE 29-UCGI 26 (NEOPAN): Quality of life results of a phase III randomised trial comparing chemotherapy with folfirinox (FFX) or gemcitabine (gem) in locally advanced pancreatic carcinoma (LAPC)
Presenter: Michel Ducreux
Session: Poster session 22
1618P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
Presenter: Alison Schram
Session: Poster session 22
1620P - A phase II study of perioperative nalirifox in patients with resectable pancreatic ductal adenocarcinoma (rPDAC): Survival update and biomarkers analysis of the NITRO trial
Presenter: Davide Melisi
Session: Poster session 22
1621P - Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial
Presenter: Shubham Pant
Session: Poster session 22
1622P - D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)
Presenter: Shunsuke Kondo
Session: Poster session 22
1623P - Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study
Presenter: Dirk Arnold
Session: Poster session 22
1624P - Predictive factors for treatment success of second-line Nal-IRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) (AIO-PAK-0216)
Presenter: Manfred Lutz
Session: Poster session 22